Eczematous dermatosis and thrombocytosis induced by efalizumab: two new side effects.
Efalizumab was authorized to be put on the market in France starting July 21, 2005. Its efficacy and tolerance profile in plaque psoriasis at a dose of 1 mg kg(-1) weekly in a subcutaneous injection have been studied in phase III trials. At the current moment, more than 3,500 patients have been included in clinical trials. Flu-like symptoms (fever, chills, headaches, nausea, vomiting, myalgia) are the most frequent adverse events. On the skin, a localized papular rash or the aggravation of the psoriasis in an edematous or even pustular form are the two most regularly observed complications. At the biological level, hyperlymphocytosis and a temporary increase in alkaline phosphatases without clinical consequences are the most frequent anomalies. We report 2 adverse events under efalizumab that to our knowledge have never been described: a case of an eczematous rash and a case of thrombocytosis.
Firmin
D
D
Department of Dermatology, University Hospital, Brest, France. firmindelphine@hotmail.com
Roguedas
A M
AM
Lemasson
G
G
Abgrall
J F
JF
Misery
L
L
D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D004485:Eczema / Q000139:chemically induced*; D005260:Female; D006801:Humans; D007279:Injections, Subcutaneous; D008297:Male; D011565:Psoriasis / Q000188:drug therapy; D013922:Thrombocytosis / Q000139:chemically induced*
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C472181:efalizumab